Related Experiment Video
Updated: Jan 30, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics
Ananya Pal1, Hsin Yao Chiu1, Reshma Taneja1
1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
Abstract:
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma accounting for 5-8% of malignant tumours in children and adolescents. Children with high risk disease have poor prognosis. Anti-RMS therapies include surgery, radiation and combination chemotherapy. While these strategies improved survival rates, they have plateaued since 1990s as drugs that target differentiation and self-renewal of tumours cells have not been identified. Moreover, prevailing treatments are aggressive with drug resistance and metastasis causing failure of several treatment regimes. Significant advances have been made recently in understanding the genetic and epigenetic landscape in RMS. These studies have identified novel diagnostic and prognostic markers and opened new avenues for treatment. An important target identified in high throughput drug screening studies is reactive oxygen species (ROS). Indeed, many drugs in clinical trials for RMS impact tumour progression through ROS. In light of such emerging evidence, we discuss recent findings highlighting key pathways, epigenetic alterations and their impacts on ROS that form the basis of developing novel molecularly targeted therapies in RMS. Such targeted therapies in combination with conventional therapy could reduce adverse side effects in young survivors and lead to a decline in long-term morbidity.
Insights
Reactive oxygen species (ROS) are a promising target for rhabdomyosarcoma (RMS) treatment. Targeting ROS and epigenetic alterations may lead to novel therapies for this childhood cancer.
Area of Science:
- Pediatric Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, with high-risk cases having a poor prognosis.
- Current therapies (surgery, radiation, chemotherapy) have shown limited improvement since the 1990s due to drug resistance and metastasis.
- Recent advances in understanding RMS genetics and epigenetics have identified potential new therapeutic targets.
Purpose of the Study:
- To review recent findings on key pathways, epigenetic alterations, and their impact on reactive oxygen species (ROS) in RMS.
- To highlight the potential of targeting ROS for novel molecularly targeted therapies in RMS.
- To discuss how these targeted therapies could improve outcomes when combined with conventional treatments.
Main Methods:
- Literature review of recent studies on RMS genetics, epigenetics, and therapeutic targets.
- Analysis of the role of reactive oxygen species (ROS) in RMS progression.
- Synthesis of information on emerging molecularly targeted therapies.
Main Results:
- Reactive oxygen species (ROS) have been identified as a significant target in high-throughput drug screening for RMS.
- Many drugs currently in clinical trials for RMS exert their effects by modulating ROS.
- Epigenetic alterations play a crucial role in RMS development and present opportunities for targeted intervention.
Conclusions:
- Targeting ROS, alongside epigenetic modifications, offers a promising strategy for developing novel molecularly targeted therapies for RMS.
- Combination therapy involving novel targeted agents and conventional treatments could improve survival rates and reduce long-term side effects in pediatric RMS patients.
- Further research into the interplay between genetic/epigenetic factors and ROS is essential for advancing RMS treatment.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Balancing Redox Equations
Redox Reactions
Redox Reactions
What is Homeostasis?

